Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)

Detalles Bibliográficos
Main Authors:	Schmidt, C, Kochhar, S, Excler, J, Smith, C, McMichael, A, Hanke, T, Bwayo, J, Jaoko, W, Weber, J, Kaleebu, P, Peters, B, Pantaleo, G, Vardas, E, Vasan, S, Keefer, M, Ramanathan, V, Boyle, R, Fast, P
Formato:	Conference item
Publicado:	2008

Títulos similares

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
por: Peters, B, et al.
Publicado: (2007)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
por: Hanke, T, et al.
Publicado: (2002)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
por: Jaoko, W, et al.
Publicado: (2008)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
por: Cottingham, M, et al.
Publicado: (2008)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
por: Howles, S, et al.
Publicado: (2010)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
por: Dorrell, L, et al.
Publicado: (2007)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
por: Mwau, M, et al.
Publicado: (2004)

Clinical development of Modified Vaccinia virus Ankara vaccines.
por: Gilbert, S
Publicado: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
por: Gilbert, S
Publicado: (2013)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
por: Estcourt, M, et al.
Publicado: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
por: Dorrell, L, et al.
Publicado: (2000)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
por: Rosario, M, et al.
Publicado: (2010)

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs
por: Busquets, N, et al.
Publicado: (2011)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
por: Hanke, T, et al.
Publicado: (2007)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
por: Sharpe, S, et al.
Publicado: (2003)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
por: Moorthy, V, et al.
Publicado: (2003)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
por: Hanke, T, et al.
Publicado: (1998)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
por: Slyker, J, et al.
Publicado: (2005)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
por: Gilbert, S, et al.
Publicado: (1999)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
por: Winstone, N, et al.
Publicado: (2009)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
por: Smith, C, et al.
Publicado: (2005)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
por: López-Camacho, C, et al.
Publicado: (2019)

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
por: Wee, E, et al.
Publicado: (2002)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
por: McConkey, S, et al.
Publicado: (2003)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
por: Schneider, J, et al.
Publicado: (1998)

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
por: Hanke, T, et al.
Publicado: (2005)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
por: Alharbi, N
Publicado: (2014)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
por: Hanke, T, et al.
Publicado: (1999)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
por: Alharbi, N, et al.
Publicado: (2015)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
por: Allen, T, et al.
Publicado: (2000)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
por: Ondondo, B, et al.
Publicado: (2006)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
por: Hanke, T, et al.
Publicado: (2008)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
por: Im, E, et al.
Publicado: (2006)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
por: Behboudi, S, et al.
Publicado: (2004)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
por: Bejon, P, et al.
Publicado: (2006)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
por: Moorthy, V, et al.
Publicado: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
por: Moorthy, V, et al.
Publicado: (2003)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
por: Winslow, R, et al.
Publicado: (2017)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
por: Milligan, I, et al.
Publicado: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
por: Milligan, I, et al.
Publicado: (2016)